BEAM Q4 2023 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$316M+1478.0% YoY

Gross Profit

$176M55.7% margin

Operating Income

$133M42.0% margin

Net Income

$143M45.2% margin

EPS (Diluted)

$1.73

QoQ Revenue Growth

+1739.1%

Cash Flow

Operating Cash Flow

$135M

Free Cash Flow

$131M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$478M

Stockholders' Equity

$981M

Cash & Equivalents

$436M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$316M	$20M	+1478.0%
Gross Profit	$176M	-$66M	+365.6%
Operating Income	$133M	-$89M	+249.3%
Net Income	$143M	-$38M	+472.4%